For the quarter ending 2025-09-30, CRBU had -$14,057K decrease in cash & cash equivalents over the period. -$25,300K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Licensing and collaboration revenue | 2,198 | - |
| External costs | 12,285 | - |
| Internal costs | 8,364 | - |
| Total research and development | 20,649 | - |
| General and administrative | 7,389 | - |
| Other segment items | 3,560 | - |
| Other income, net | 11,402 | - |
| Net loss | -27,548 | -94,089 |
| Depreciation and amortization | 631 | 2,332 |
| (gain) loss on disposal of fixed assets | 0 | 25 |
| Non-cash consideration for licensing and collaboration revenue | 0 | 9 |
| Change in fair value of equity securities | 12 | 4 |
| Stock-based compensation expense | 2,931 | 7,011 |
| Change in fair value of mskcc success payments liability | 0 | -785 |
| Acquired in-process research and development | 0 | 0 |
| Accretion of discounts on investments in marketable securities, net | 235 | 745 |
| Impairment charges | 0 | 12,150 |
| Impairment of equity investment | 0 | -9,158 |
| Non-cash lease expense | 457 | 965 |
| Accounts receivable | 171 | -194 |
| Contract assets | 107 | -405 |
| Other receivables | -129 | 129 |
| Prepaid expenses and other current assets | -461 | -811 |
| Other assets | 155 | -1,896 |
| Accounts payable | 561 | 774 |
| Accrued expenses and other current liabilities | -1,111 | -2,413 |
| Deferred revenue, current and long-term | -627 | -1,845 |
| Operating lease liabilities | -389 | -635 |
| Net cash used in operating activities | -25,185 | -64,983 |
| Proceeds from maturities of marketable securities | 68,414 | 122,628 |
| Purchases of marketable securities | 57,448 | 47,751 |
| Purchases of property and equipment | 115 | 1,460 |
| Payments to acquire in-process research and development | 0 | 0 |
| Net cash provided by investing activities | 10,851 | 73,417 |
| Proceeds from exercise of stock options | 0 | 6 |
| Proceeds from issuances of common stock under espp | 277 | 468 |
| Proceeds from issuances of common stock related to atm, net of offering expenses | 0 | 0 |
| Net cash provided by financing activities | 277 | 474 |
| Net decrease in cash, cash equivalents, and restricted cash | -14,057 | 8,908 |
| Cash and cash equivalents at beginning of period | 16,339 | - |
| Cash and cash equivalents at end of period | 11,190 | - |
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)